In the Zone: biomarkers in drug development – why strategy matters

Biomarkers are reshaping the future of drug discovery and development with the promise of gaining an understanding of disease and possible treatments at the individual level and progressing the vision towards personalized medicine. Despite their promise, the journey to unlocking the full potential of biomarkers is not without its challenges. Turning biomarker data into meaningful insights is no easy task, as they can be difficult to measure with precision.

A well-designed biomarker strategy is essential for clinical success. By integrating cleaner sample preparation, robust separations and high-sensitivity detection, LC–MS workflows are enabling researchers to generate data with confidence to tackle the inherent complexity of biomarker analysis. 

In this In the Zone feature, we explore how a strong biomarker strategy, powered by LC–MS, can help overcome complexity, accelerate development and drive real impact in the clinic.

[Video by Kristian Baycroft-Willmott]

INFOGRAPHIC

Breaking through the complexity of biomarker quantification

This infographic highlights some of the challenges associated with biomarkers, which can arise due to their diversity, difficulties in measuring various data and the pressures of different compliance and standardization. Explore methods to overcome the complexities of biomarkers and how a vital tool such as LC–MS can address these challenges by providing more reliable, accurate and precise data and quantification.

In association with: